Hyperhidrosis, also known as excessive sweating, does not typically pose a serious threat to a person’s health. It can, however, be embarrassing and distressing. The inconvenience can also have a negative impact on your quality of life.
Excessive Sweating – Hyperhidrosis
There is not such a way of defining excessive sweating. But if sweating is interfering with your daily life and normal activities, you may have hyperhidrosis.
A lot of people with the condition are too embarrassed to seek medical help or believe that nothing can be done to improve their symptoms.
However, there is help available.
Botulinum neurotoxin, also called Botox ®, treatment helps control the symptoms of severe underarm sweating. It is used when topical medicines have not worked for you. Botulinum neurotoxin works by temporarily blocking chemical signals from the nerves that stimulate the sweat glands. When the sweat glands do not receive chemical signals, the severe sweating stops. But it also works well on excessive facial sweating, like on the upper lip or forehead.
Is hyperhidrosis common?
Yes, you are not alone. More than 7.5 million people are affected by excessive sweating. There has been a 32 per cent increase in Google searches for ‘excessive sweating’ in 2019, and the number is raising.
Botulinum toxin injections are expected to temporarily stop the production of excessive sweat in the treated areas only. Sweat continues to be produced elsewhere. So please do not worry. It does not require anesthesia and you can return to their normal routine immediately. In most cases, the treatment lasts between 4-12 months.
Hyperhidrosis: Evolving therapies for a well-established phenomenon. Eisenach JH, et al. Mayo Clinic Proceedings. 2005; 80:657.
Hyperhidrosis (Excessive sweating). Barbara Woodward Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2011.
Botulinum toxin for focal hyperhidrosis of the face. George SM, Atkinson LR, Farrant PB, Shergill BS; Br J Dermatol. 2013 Aug 5. doi: 10.1111/bjd.12568.
Treatment of primary axillary hyperhidrosis with botulinum toxin type a: our experience in 50 patients from 2007 to 2010. Scamoni S, Valdatta L, Frigo C, Maggiulli F, Cherubino M. ISRN Dermatol. 2012; 2012